Vertex Pharmaceuticals

Applied Materials exists to power the technological revolution by enabling the creation of virtually every new semiconductor and advanced display in the world. As the semiconductor industry faces unprecedented demand for chips that power AI, smartphones, electric vehicles, and the cloud, Applied Materials provides the critical materials engineering solutions that make next-generation chip manufacturing possible. Without these foundational technologies, the digital transformation transforming every aspect of modern life would stall. For over five decades, Applied Materials has pushed the boundaries of science and engineering to solve the industry's most complex challenges - from shrinking transistors to atomic scales to developing new materials that enable faster, more efficient computing. Their equipment, software, and services are essential to advancing AI and accelerating the commercialization of next-generation chips, ensuring that the pace of innovation continues to accelerate.

We've been crafting products that help people access clean, refreshing water since 1920, when our founders Leopold Katz, his son Louis, and a tinsmith named Ellef Robarth started hand-fabricating sinks on Chicago's Near North Side. What began as a small operation with three people has grown into America's leading kitchen sink company and a trusted name in water delivery solutions. Today, we design and manufacture sinks, faucets, water coolers, and bottle filling stations that you'll find in homes, schools, airports, offices, and healthcare facilities across the country. We're proud to be family-owned for over a century, and we're now part of Zurn Elkay Water Solutions, which means we can offer an even broader range of products that help make everyday life a little better. Whether it's a residential quartz sink that becomes the heart of a kitchen or a commercial bottle filling station that keeps a campus hydrated sustainably, we build products that last and that people can depend on.

Orbis is a veteran-owned engineering solutions company founded in 2000, working almost exclusively for the U.S. Department of Defense across a nearly 300-person, seven-location U.S. workforce. The threat model here is defense-grade: systems that fail or get compromised don't just generate incident reports - they affect naval operations, weapons readiness, and allied interoperability. Orbis operates across the full DoD acquisition and modernization lifecycle, supporting Navy programs including SEA 21 and NAVSEA, with a particular focus on naval ship modernization, automated test systems, and cybersecurity solutions for defense-related systems. On the cyber side, Orbis sits inside a stack that includes systems integration, IT and software development, radiation detection, and test engineering - meaning security work here is embedded in complex, hardware-adjacent environments, not siloed enterprise IT. Defense contractors operating at this level work under frameworks like RMF (Risk Management Framework) and CMMC compliance requirements, and the work tends to involve classified or sensitive systems where misconfigurations carry real operational consequences. ISO 9001 certification signals a process-disciplined environment where documentation and repeatability are non-negotiable. Orbis's recent move to acquire Canopy Design Lab and its selection as Australia's ASC submarine company's first U.S. AUKUS capability collaboration partner point toward an expanding operational footprint - AUKUS technology-sharing obligations come with significant cybersecurity and supply chain security requirements under both U.S. and allied frameworks. The company spans defense and space manufacturing verticals, which means the attack surface and compliance landscape are both broadening. Domains: Cybersecurity solutions, systems integration, IT and software development, automated test systems, naval ship modernization Programs: SEA 21, NAVSEA, AUKUS capability collaboration Certifications: ISO 9001, Veteran-Owned Small Business (VOSB) Footprint: Seven U.S. locations, international partnership with Australia's ASC

We are a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. Our team comes to work every day with a sustained commitment to improving human health - and it's what pushes us to innovate. At Deciphera, we are united in our goal to defeat cancer by addressing key mechanisms of tumor and drug resistance that limit the results of some existing therapies. We leverage our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. Since becoming a member of ONO Group in June 2024, we have continued expanding our global footprint while maintaining our dedication to patients. We design switch-control kinase inhibitors with the goal of potentially improving patient responses to treatment and, ultimately, patient outcomes.

We are a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide. Founded in 2014, we began as an early-stage cell therapy company with the vision of bringing novel therapies to patients suffering from chronic and life-threatening conditions. We entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autoleucel (cilta-cel). Our strategic partnership is designed to combine the strengths and expertise of both companies to advance the promise of immunotherapy in the treatment of multiple myeloma.

Oxford Nanopore Technologies develops and commercializes a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible and easy to use. The company's nanopore sequencing platform offers real-time analysis in fully scalable formats from pocket-sized devices like MinION to high-throughput benchtop systems like PromethION. The technology uniquely sequences native DNA and RNA, enabling short to ultra-long read lengths without the need for amplification or labeling. Founded in 2005 as a spin-out from the University of Oxford, the company employs more than 1000 people across multiple disciplines including nanopore science, molecular biology, informatics, engineering, and manufacturing. Oxford Nanopore's goal is to enable the analysis of anything, by anyone, anywhere. The technology is used across scientific research, healthcare, and industrial applications, powering breakthroughs in microbial genomics, human genomics, cancer research, infectious disease surveillance, and environmental studies in over 120 countries worldwide.